Eli Lilly Omvoh Demonstrates Sustained Long-Term Benefits in Ulcerative Colitis Up to Four Years

Eli Lilly and Company (NYSE:LLY) is one of the best growth stocks to buy now. On October 7, Eli Lilly and Company announced new data from the LUCENT-3 Phase 3 open-label extension study demonstrating that its drug, Omvoh (mirikizumab-mrkz), is the first and only interleukin-23p19 (IL-23p19) antagonist to provide patients with moderately to severely active ulcerative colitis/UC with sustained, long-term comprehensive outcomes for up to four years.

The results showed benefits across multiple symptomatic, clinical, endoscopic, histologic, and quality-of-life measures, including in patients who had previously failed a biologic or advanced therapy (27% of the study population). The LUCENT-3 study evaluated patients who achieved clinical remission with Omvoh after one year in the Phase 3 LUCENT-2 study.

The long-term safety profile of Omvoh in patients with moderately to severely active UC remained consistent with its known profile, with no new safety signals observed. Among patients who completed one year of blinded Omvoh maintenance therapy in LUCENT-2 and continued into LUCENT-3, 12% reported a serious adverse event, and 7% discontinued treatment due to an adverse event.

Eli Lilly and Company (NYSE:LLY) discovers, develops, and markets human pharmaceuticals in the US, Europe, China, Japan, and internationally.

While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.